Susanne Schmitz

Latest publications

Examining the feasibility and utility of estimating partial expected value of perfect information (via a nonparametric approach) as part of the reimbursement decision-making process in ireland: application to drugs for cancer.

  • Health Economics and Evidence Synthesis Research Unit
November 01, 2017
2017 Nov. Pharmacoeconomics.35(11):1177-1185.
By:
  • McCullagh L
  • Schmitz S
  • Barry M
  • Walsh C.

The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers.

  • Health Economics and Evidence Synthesis Research Unit
October 01, 2017
2017 Oct. Br J Clin Pharmacol.83(10):2235-2241. Epub 2017 Jun 27.
By:
  • Liddy AM
  • McLaughlin G
  • Schmitz S
  • D'Arcy DM
  • Barry MG.

Harms of off-label erythropoiesis-stimulating agents for critically ill people.

  • Health Economics and Evidence Synthesis Research Unit
August 25, 2017
2017 Aug. Cochrane Database Syst Rev.8:Cd010969.
By:
  • Mesgarpour B
  • Heidinger BH
  • Roth D
  • Schmitz S
  • Walsh CD
  • Herkner H.

Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?

  • Health Economics and Evidence Synthesis Research Unit
January 01, 2017
2017 Jan. J Comp Eff Res.6(1):65-82. Epub 2016 Nov 17.
By:
  • Gray E
  • Norris S
  • Schmitz S
  • O'Leary A.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

  • Health Economics and Evidence Synthesis Research Unit
September 01, 2016
2016 Sep. Mult Scler Relat Disord.9:23-30. Epub 2016 Jun 8.
By:
  • Fogarty E
  • Schmitz S
  • Tubridy N
  • Walsh C
  • Barry M.